Low HDL Cholesterol Clinical Trial
Official title:
The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid
The effect of fibrates on high density lipoprotein (HDL)-cholesterol levels is suggested to
be mediated by its binding to peroxisome proliferator-activated receptor-g (PPARg). Upon
ligand binding, PPARg heterodimerizes with the 9-cis retinoic acid receptor (RXR), and the
heterodimer regulates gene expression. We assessed the hypothesis that a dual treatment with
fibrate plus 9-cis b-carotene-rich powder of the alga Dunaliella bardawil, as a source of
9-cis retinoic acid, would improve the drug's effect on HDL-cholesterol levels.
patients with plasma HDL-cholesterol levels below 40 mg/dl and triglyceride (TG) levels
above 200 mg/dl after fibrate treatment (for at least 6 weeks). are given four capsules of
Dunaliella, providing 60 mg b-carotene/day. The all-trans to 9-cis b-carotene ratio in the
capsules is about 1:1.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02106013 -
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals
|
N/A |